Latest News and Press Releases

HÄNDELSER FJÄRDE KVARTALET Genomförd riktad nyemission om cirka 165 MSEK före emissionskostnaderNy styrelse valdes på extra bolagsstämma den 19 marsNy styrelse inleder genomlysning av situationen i...

EVENTS IN FOURTH QUARTER Private placement of approximately MSEK 165 before issue expenses carried outNew Board of Directors elected at Extraordinary General Meeting on March 19New Board initiates...

The Board of Oasmia has decided to report certain suspicious transactions that has been made by the company during several years to the Swedish Economic Crime Authority. In connection with a tax...

Sven Rohmann, MD PhD MBA, has today been appointed as acting CEO of Oasmia Pharmaceutical AB. He assumes his new role July 1, 2019. Since March 2019 Sven Rohmann has been a member of the Board of...

Oasmia kommer att hålla en audiocast och telefonkonferens fredagen den 28 juni klockan 09:00 (CET) för genomgång av bolagets bokslut för räkenskapsåret 2018/2019 samt presentera status i styrelsens...

Oasmia will hold an audiocast and telephone conference on Friday 28 June at 09:00 (CET) to present the company's full-year report for the financial year 2018/2019 and the status of the board's...

Oasmia Pharmaceutical AB (NASDAQ:OASM) presenterar idag resultaten från två kliniska studier av läkemedelskandidaten Docecal i patienter med metastaserande bröstcancer. Docecal är en nyutvecklad...

Oasmia Pharmaceutical AB (NASDAQ: OASM) reports on the results from the two clinical studies using Docecal in patients with metastatic breast cancer. Docecal is a newly developed formulation of...

Styrelsen i Oasmia har beslutat att senarelägga publiceringen av rapporten för fjärde kvartalet och bokslutskommunikén 2018/2019 från 5 juni 2019 till 28 juni 2019. Förseningen är ett resultat av den...

The Board of Oasmia has decided to postpone the release of the fourth quarter and year-end 2018/2019 report from 5 June 2019 to 28 June 2019. The delay is a result of the ongoing review...